關(guān)鍵詞： GSK 節(jié)省開支 歐洲市場(chǎng)
2013年2月7日訊 /生物谷BIOON/ --GSK公司CEO Andrew Witty向媒體表示,，為了應(yīng)對(duì)來(lái)自歐洲市場(chǎng)日益增大的價(jià)格競(jìng)爭(zhēng)壓力,，從現(xiàn)在到2016年,，公司計(jì)劃通過對(duì)研發(fā)部門,、制藥部門以及銷售部門的一系列措施來(lái)使公司每年削減10億歐元的經(jīng)費(fèi),。Witty并未透露這次計(jì)劃中裁員的具體數(shù)目,，但是他表示這次裁員將主要發(fā)生在管理部門和銷售部門中,。這在一定程度上也表明了GSK公司對(duì)目前歐洲糟糕的經(jīng)濟(jì)狀況的擔(dān)憂并希望借此來(lái)降低產(chǎn)品價(jià)格以增強(qiáng)競(jìng)爭(zhēng)力,。
GSK公司也希望繼續(xù)在研發(fā)過程中取得突破以擴(kuò)大公司的市場(chǎng)份額,。2013年被認(rèn)為是GSK公司大獲豐收的一年，從去年開始,，公司先后提交了6種藥物,，其中包括治療肺病的Breo和Anoro, 治療黑色素瘤的藥物trametinib 和 dabrafenib, 治療HIV的藥物 dolutegravir 以及治療二型糖尿病的 albiglutide。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
In reaction to pricing pressure in Europe, GlaxoSmithKline ($GSK) aims to chop ?1 billion ($1.57 billion) in annual spending in Europe, R&D and manufacturing by 2016, the drugmaker revealed today in its fourth-quarter earnings. The London-based pharma giant intends to seek cost reductions through technical improvements in research and manufacturing, but GSK CEO Andrew Witty expects job cuts to be part of the European cost savings.
Talking with analysts today, Witty didn't reveal any numbers of jobs to be slashed through the savings plan but noted that the majority of the impact on workers would be in administrative and sales units in Europe. And while touting the 6 new drugs under review and data expected from late-stage studies of 9 new drugs over the next two years, GSK signaled its growing angst about the troubling economic situation in Europe and resulting pricing pressures on its business.
Glaxo expects to get the bulk of its cost savings in manufacturing and R&D through modernizing labs and research processes as well as new approaches to producing drugs rather than layoffs, a company spokeswoman told FierceBiotech in an email. The cutbacks are expected to cost the company ?1.5 billion ($2.34 billion) and primarily impact Europe, where sales dropped 7% as European authorities clamped down on drug pricing and reimbursements, Bloomberg reported."We are very serious about looking for the right strategic response" in Europe, Witty told analysts in a meeting webcasted today. He noted that 80% of the market exists outside of Europe, presenting opportunities for the company in other regions.
2013 is bound to be an exciting year for GSK's vaunted pipeline and lineup of new meds under regulatory review. Since last year the company has filed for approval of 6 drugs including the inhaled asthma and COPD drug Breo, a LAMA/LABA med for COPD dubbed Anoro, a pair of melanoma drugs known as trametinib and dabrafenib, the HIV med dolutegravir and albiglutide for Type 2 diabetes.
With data from late-stage studies of 14 assets expected over the next two years, GSK watchers are in for a wild ride as not all the programs are expected to succeed. Shares of GSK lagged the European pharma index last year, but the company aims to mount a comeback by launching up to 15 products over the next three years.
"There will be lots of moments where I'm going to be very nervous, you're going to be very interested and we'll see how we both feel in the morning," Witty told analysts.
"[2013] is going to be one of those sorts of years," the CEO added. "It's a very different sort of atmosphere for us. Obviously there's going to be lots of twists and turns. Not everything is going to go smoothly."
